PD1 signal transduction pathways in T cells
Metrics: PDF 3002 views | HTML 3213 views | ?
Hugo Arasanz1,*, Maria Gato-Cañas1,*, Miren Zuazo1,*, Maria Ibañez-Vea1,*, Karine Breckpot3, Grazyna Kochan1 and David Escors1,2
1Immunomodulation Group, Navarrabiomed-Biomedical Research Centre, IdISNA, Pamplona, Spain
2Rayne Institute, Division of Infection and Immunity, University College London, London, United Kindom
3Laboratory of Molecular and Cellular Therapy Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium
*These authors have contributed equally to this work
David Escors, email: firstname.lastname@example.org
Grazyna Kochan, email: email@example.com
Keywords: PD-L1, PDL1, PD1, B7-H1, cancer
Received: February 28, 2017 Accepted: March 24, 2017 Published: April 19, 2017
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.